Population
159 participants, comprising 86 patients diagnosed with acute coronary syndrome and 73 healthy controls. ACS…
Design
Case-control
Key result
Serum miR-744-5p was significantly downregulated in patients with acute coronary syndrome, demonstrating high diagnostic efficacy with an AUC of 0.9103.
Authors
Loading...
Supports miR-744-5p as potential ACS biomarker; extends prior observations but leaves open clinical adoption pending prospective validation.
Case-Control (n=159)
No
Effect estimate: AUC 0.9103 (95% CI 0.8579-0.9627)
p-value: p=<0.0001
Serum miR-744-5p is significantly downregulated in acute coronary syndrome, demonstrating high diagnostic potential while mechanistically attenuating endothelial injury and inflammation by targeting FLNA.
Wang et al. (2026) conducted a case-control in Acute coronary syndrome (n=159). Serum miR-744-5p vs. Healthy controls was evaluated on Diagnostic performance for acute coronary syndrome (AUC 0.9103, 95% CI 0.8579-0.9627, p=<0.0001). Serum miR-744-5p was significantly downregulated in patients with acute coronary syndrome, demonstrating high diagnostic efficacy with an AUC of 0.9103.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: